Publications by authors named "A M Ciudad"
Introduction: The efficacy of galcanezumab has been demonstrated in randomized controlled trials, but evidence about its use under clinical practice conditions is still limited. This study aimed to describe the characteristics of the patients treated with galcanezumab in routine clinical practice in Spain as well as treatment patterns, persistence, and effectiveness.
Methods: A retrospective chart review study was carried out in six hospitals.
Article Synopsis
- Solar urticaria is a rare skin condition triggered by sunlight, affecting 41 patients in a study that analyzed long-term outcomes and treatment approaches, particularly with omalizumab over 16 years.
- The study found that treating patients with omalizumab resulted in significant improvements in symptoms, as indicated by decreased levels of the high-affinity IgE receptor (FcεRI) and enhanced Urticaria Control Test scores.
- Despite a high drug survival rate of 88.9% at 48 months, only one patient successfully discontinued omalizumab on a stepping-down protocol, suggesting that ongoing monitoring and treatment may be necessary for most patients.